Biolevate lands €30M Series A to scale life sciences AI

Life sciences AI company Biolevate has
raised €30 million in Series A funding to expand its platform for automating
scientific and regulatory workflows and support its international growth. The
round was co-led by RAISE France, the investment vehicle of French entrepreneur
Aymar Hénin, and Orange Ventures, with participation from MSD Global Health Innovation Fund (MGHIF), Station F and existing investor EQT Ventures.

Founded in Paris by a team of former
Dataiku engineers and AI researchers, Biolevate is targeting operational
bottlenecks across the life sciences industry. As AI accelerates drug discovery
and development, the company says pharmaceutical businesses face growing
pressure to manage scientific and regulatory processes involved in bringing
therapies to market.

Biolevate has developed an enterprise
agentic AI platform that turns scientific and regulatory knowledge into
auditable workflows. The platform is designed to keep its outputs grounded in
source evidence, allowing life sciences organisations to use AI in regulated
environments while maintaining human oversight.

Initially developed to accelerate
regulatory approval workflows, the platform now covers areas across the life
sciences value chain, including research, clinical trials, health technology
assessments, regulatory dossiers, drug discovery and drug development. It can
run up to 100,000 agents concurrently.

Biolevate says its platform has
accelerated systematic literature reviews and research synthesis sixteenfold
and delivered an 80 per cent efficiency gain in regulatory intelligence and
compliance.

Since its seed round in 2024,
Biolevate has expanded its partnerships and customer base across the life
sciences sector. The company says it now serves more than a dozen enterprise
customers and has reported growth in annual recurring revenue over the past
year.

We started Biolevate with a
mission-driven team united by the belief that AI could improve millions of
lives if we empowered the right people and solved the right technological
challenges. Today, our vision is becoming reality. Customers are increasingly
embracing AI automation at scale, grounded in evidence and under rigorous human
oversight,

said Joël Belafa, co-founder and CEO
of Biolevate.

He added that the new funding and the
company’s recent growth reinforce Biolevate’s plans to scale globally and
expand the use of AI across healthcare.

The Series A coincides with
Biolevate’s expansion into the US, where it is opening an office in Boston. The
company has doubled its headcount over the past year and expects to double its
workforce again over the coming year. It has also drafted seven patent
applications across several therapeutic areas, two of which have been filed in
Europe.